News
TELA
1.150
+0.88%
0.010
TELA Bio Is Maintained at Buy by Lake Street
Dow Jones · 5d ago
TELA Bio Price Target Cut to $3.00/Share From $6.00 by Lake Street
Dow Jones · 5d ago
Lake Street Maintains Buy on TELA Bio, Lowers Price Target to $3
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Centessa Pharmaceuticals (CNTA)
TipRanks · 5d ago
Tela Bio price target lowered to $3 from $6 at Lake Street
TipRanks · 5d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 5d ago
Weekly Report: what happened at TELA last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at TELA last week (1117-1121)?
Weekly Report · 11/24 09:20
TELA Bio Inc. to Present at Piper Sandler 37th Annual Healthcare Conference
Reuters · 11/19 13:30
Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 11/18 12:34
TELA Bio Price Target Cut to $4.00/Share From $7.00 by Canaccord Genuity
Dow Jones · 11/18 12:02
TELA Bio Is Maintained at Buy by Canaccord Genuity
Dow Jones · 11/18 12:02
Strategic Initiatives and Financial Adjustments Underpin Buy Rating for TELA Bio Despite Short-term Challenges
TipRanks · 11/18 11:56
Canaccord Genuity Maintains Buy on TELA Bio, Lowers Price Target to $4
Benzinga · 11/18 11:52
Tela Bio price target lowered to $4 from $7 at Canaccord
TipRanks · 11/18 11:15
NOTV, APLT Lead After-Hours Biotech Gains; ALMS, TELA, CORT, BRTX Also Advance
NASDAQ · 11/18 04:33
Major Investment Alert: EW Healthcare Partners Fund 2 Acquires Millions in TELA Bio Stock
TipRanks · 11/18 02:05
EW Healthcare Partners Fund 2 Acquires Common Shares of TELA Bio Inc
Reuters · 11/17 21:26
TELA Bio Grants Stock Options and Restricted Units to New Employees
Reuters · 11/17 21:05
TELA BIO ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 11/17 21:05
More
Webull provides a variety of real-time TELA stock news. You can receive the latest news about Tela Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TELA
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.